Key Takeaways
- Biosort raised more than $10 million from aquaculture and technology investors
- Investors include Grieg Kapital, Hatch Blue, IVC, Farvatn, and Futurum Ventures
- Funding supports final development and commercialization of its lice control system
- Technology enables early-stage lice removal and individual salmon tracking
- Company aims to reduce well-boat treatments and improve fish welfare
Biosort Raises $10 Million to Advance Commercial Launch
Biosort has secured more than NOK 100 million (approximately $10 million) from a consortium of aquaculture and technology investors to bring its individual-based lice control system to market. Investors participating in the round include Grieg Kapital, Hatch Blue, IVC, Farvatn, Futurum Ventures, along with existing shareholders.
The capital will support the final development phase and commercial rollout of Biosort’s next-generation lice control technology. The system is designed to remove sea lice at an early stage, aiming to prevent population growth and reduce the need for full-pen well-boat treatments.
Geir Stang Hauge, CEO of Biosort, said: “This funding takes us from development into commercial sales. Our focus is simple: continuous lice removal to suppress lice development and greatly reduce needs for well-boat treatments. The goal is improved welfare, lower mortality, better biological control, and ultimately making fish thrive.”
